New Zealand markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
54.27+1.23 (+2.32%)
At close: 04:02PM EST
54.08 -0.19 (-0.35%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close53.04
Bid0.00 x 1200
Ask0.00 x 3000
Day's range53.10 - 54.41
52-week range33.36 - 55.70
Avg. volume33,175,322
Market cap304.61B
Beta (5Y monthly)0.67
PE ratio (TTM)15.50
EPS (TTM)3.50
Earnings date31 Jan 2022 - 04 Feb 2022
Forward dividend & yield1.56 (2.87%)
Ex-dividend date04 Nov 2021
1y target estN/A
  • Motley Fool

    Why Moderna Is the Biggest Winner From COVID Boosters So Far

    Some Americans could prefer Moderna's booster because of perceptions that it offers higher efficacy.

  • Motley Fool

    Here's Why Merck Lost Nearly $40 Billion in Value During November

    Shares of pharma giant Merck (NYSE: MRK) fell by 14.9% during the month of November, according to data from S&P Global Market Intelligence. Although the drugmaker did take a hit from a clinical setback for its once-weekly oral treatment, MK-8507, for HIV-1 infection last month, the main reason Merck's stock slumped in November is the evolving situation surrounding its oral coronavirus pill molnupiravir. In brief, this COVID-19 pill, which is being jointly developed with privately held Ridgeback Biotherapeutics, exhibited a significant drop in efficacy following the final analysis of the full data set, compared to a prior interim data readout.

  • Yahoo Finance

    Guess who pays for all those millions of COVID-19 vaccines

    Omicron happened this week. So as the medical world shifts to a yet-to-be-determined degree, a question comes to mind: Who will pay for all this? In fact, who’s paid for all the COVID fighting to date?